This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Genable utilizes well-established, clinically safe & effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
The combination of suppression and replacement (S&R) overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders. Genable's technology is protected by a broad suite of granted patents and patent applications in the USA, EU and worldwide.
Opsona's lead product, a fully humanized monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of preclinical models and has been tested in a Phase I clinical trial in healthy volunteers. Recently the company has initiated a three-part multi-centred, double blinded and placebo controlled Phase II clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical indication for the development of OPN-305. The first part of this Phase II has been completed in transplant patients. The second part is ongoing in transplant patients.
OPN-305 has obtained EMA and FDA orphan drug status in Solid Organ Transplantation. Opsona has been awarded a EUR 5.9 million grant from the European Commission in 2010 to lead a European framework 7 (FP7) consortium of research and clinical groups (MABSOT )to help advance OPN-305 through clinical development.
Opsona?s second programme is targeting the Inflammasome, strategically complementing our pipeline of innate immune modulators. Pathologies such as gouty arthritis, Muckle-Wells syndrome or CINCA/NOMID have been shown to be dependent on Inflammasome activity. Early development studies have confirmed drugability of the Inflammasome. Opsona is actively seeking a partnering opportunity for its small molecule Inflammasome inhibitor programme.